Intravenous Immunoglobulin Market in the 7MM is Valued at ~USD 7,384 Million in 2025 Over the Forecast Period (2025–2034)

The Intravenous Immunoglobulin (IVIG) market across the seven major markets (7MM), the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is poised for steady expansion over the coming decade. Valued at approximately USD 7,384 million in 2025, the market is projected to grow at a CAGR of 6.9%, reaching nearly USD 13,496 million by 2034.

The United States remains the dominant revenue generator, accounting for the largest share of the IVIG market in 2025. The EU4 and the United Kingdom collectively contribute a significant portion of global revenue, while Japan also represents a robust and mature market for IVIG therapies.

IVIG is a cornerstone therapy for a broad range of primary and secondary immunodeficiency disorders, autoimmune diseases, neuromuscular conditions, and inflammatory pathologies. The rising prevalence of conditions such as Primary Immunodeficiency Diseases (PIDs), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Kawasaki disease, Immune Thrombocytopenia (ITP), and Guillain–Barré syndrome, coupled with improved diagnostic capabilities, continues to fuel steady demand across major geographies.

The therapeutic landscape relies heavily on plasma-derived immunoglobulin products, with advances in plasma collection, fractionation technologies, and supply-chain optimization playing a crucial role in meeting global needs. Despite growing patient populations, the market continues to face challenges related to plasma supply constraints, high treatment costs, and complex manufacturing requirements.

A competitive industry ecosystem drives innovation, with leading companies such as Takeda Pharmaceutical Company Limited, CSL Behring, Octapharma AG, Baxter International Inc., Bayer AG, Shanghai RAAS Blood Products Co. Ltd, Bio Products Laboratory Ltd, and Biotest AG shaping product availability, quality, and global distribution.

Looking ahead, the IVIG market is expected to maintain strong momentum through 2034, supported by increasing clinical adoption, continued demand across neurology and immunology segments, and expanding product portfolios. Strategic collaborations, improved plasma-collection infrastructure, and emerging formulation innovations are also anticipated to help address supply-demand gaps and enhance long-term market sustainability.

DelveInsight’s report, “Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast–2034,” offers an in-depth analysis of market dynamics across the 7MM. The report provides comprehensive insights into epidemiology trends, current treatment practices, unmet needs, and emerging opportunities, enabling stakeholders to navigate the evolving IVIG market landscape with strategic clarity.

 

Some of the key facts of the Intravenous Immunoglobulin Market Report:

• The leading Intravenous Immunoglobulin Companies developing therapies include Shanghai RAAS Blood Products Co. Ltd, Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd, Biotest AG, CSL Behring, Grifols SA, Kedrion SpA, LFB Biotechnologies SAS, BDI Pharma Inc., China Biologic Products Holdings Inc., Hualan Biological Engineering Inc, ADMA Biologics Inc, and others.
• The future of Intravenous Immunoglobulin treatment holds promise, driven by ongoing research and the development of innovative therapies. Current management strategies, such as symptomatic medications, physical therapy, and supportive care, remain essential.

Intravenous Immunoglobulin Overview

Intravenous Immunoglobulin (IVIG) is a plasma-derived therapeutic product composed of pooled immunoglobulin G (IgG) antibodies collected from thousands of healthy donors. It plays a crucial role in managing a wide range of immune-related and inflammatory disorders by modulating immune responses, replacing missing antibodies, and controlling pathological autoantibody activity.

IVIG is primarily used in the treatment of primary immunodeficiency disorders (PIDs), secondary immunodeficiencies, and several autoimmune and inflammatory diseases, including immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain–Barré syndrome (GBS), Kawasaki disease, and myasthenia gravis. Its ability to rapidly stabilize immune dysfunction has positioned it as a standard and often frontline therapy across multiple specialties, such as neurology, immunology, hematology, and rheumatology.

The demand for IVIG continues to rise due to increasing diagnosis of immunodeficiency cases, expanding indications, a growing elderly population, and heightened awareness of immune-mediated diseases. Despite its clinical advantages, the market faces challenges such as high treatment costs, supply constraints linked to complex plasma collection processes, and the emergence of alternative targeted therapies.

Overall, IVIG remains a cornerstone therapy within the immunoglobulin segment, supported by ongoing research, improved manufacturing technologies, and its critical relevance in both acute and chronic immune-mediated conditions.

Learn more about Intravenous Immunoglobulin treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Intravenous Immunoglobulin Treatment Market

Key Factors Driving Growth in the Intravenous Immunoglobulin Market

• Expanding Intravenous Immunoglobulin Patient Population: The IVIG market is supported by a substantial and steadily growing patient population across multiple therapeutic areas. In the United States alone, 2024 estimates report approximately 203,000 individuals with primary immunodeficiency disorders, 58,000 with immune thrombocytopenic purpura (ITP), 21,000 with chronic inflammatory demyelinating polyneuropathy (CIDP), and 1,800 with multifocal motor neuropathy (MMN). This broad and increasing patient base continues to rise as diagnostic practices improve, disease awareness strengthens, and IVIG usage gains wider acceptance in both approved and off-label indications.
• Regulatory Approvals Strengthening the IVIG Market: A robust pipeline of approved and emerging therapies continues to shape the competitive landscape of the IVIG market. IVIG products are well-established for conditions such as ITP, Guillain–Barré syndrome, Kawasaki disease, CIDP, and MMN. Beyond these labeled indications, IVIG is widely used off-label across numerous neurological, hematological, and dermatological disorders, reinforcing its critical role in clinical management. Commercial performance also reflects its importance, BIVIGAM, for example, recorded USD 50 million in US sales in 2024, underscoring the strong market traction of IVIG therapies.
• Rising Clinical and Commercial Momentum in IVIG: The IVIG space is characterized by active participation from both long-standing leaders and new entrants. Major companies, including Shanghai RAAS Blood Products Co. Ltd, Octapharma AG, Takeda, Baxter, Bayer, Bio Products Laboratory, Biotest AG, CSL Behring, Grifols, Kedrion, ADMA Biologics, and others, are advancing market growth through strategic product development, expansion of plasma collection infrastructure, and continuous improvement in manufacturing technologies. Their combined efforts are driving significant clinical and commercial momentum across the global IVIG landscape.

 

Recent Developments in Intravenous Immunoglobulin Clinical Trials:

 

• At the 2025 Clinical Immunology Society (CIS) Annual Meeting, GC Biopharma USA presented data on improving IVIG safety by removing residual activated coagulation Factor XIa (FXIa) via cation-exchange (CEX) chromatography.
• On 30 June 2025, Takeda announced that the U.S. FDA approved GAMMAGARD LIQUID ERC, a ready-to-use (no reconstitution), low-IgA immunoglobulin (≤ 2 µg/mL IgA in 10%) solution.
• On 28 April 2025, ADMA Biologics announced that the FDA approved its innovative yield enhancement process. This process allows ~20% more immunoglobulin output from the same plasma volume.
• On 3 April 2025, the FDA approved Inebilizumab-cdon (UPLIZNA, by Amgen) for IgG4-related disease (IgG4-RD), making it the first (and only) approved therapy for this indication.

Learn more about the recent advancements in Intravenous Immunoglobulin treatment landscape @ Intravenous Immunoglobulin Recent Developments

 

Intravenous Immunoglobulin Epidemiology Segmentation

• Prevalent and diagnosed cases in the 7MM
• Age-specific segmentation in the 7MM
• Gender-specific segmentation in the 7MM
• Indication-wise segmentation in the 7MM

Intravenous Immunoglobulin Market Barriers

• Limited Plasma Supply & Manufacturing Constraints: IVIG production relies entirely on human plasma, making supply inherently constrained. Complex fractionation processes, long production cycles, and dependence on donor availability often lead to shortages and inconsistent global supply, restricting market scalability.
• High Treatment Costs: The cost of IVIG therapy remains a major barrier, particularly for chronic conditions like CIDP or primary immunodeficiencies that require lifelong treatment. High product prices, infusion costs, and hospital-based administration contribute to significant financial burden on patients and healthcare systems.
• Increasing Competition from Targeted Therapies: Emerging biologics such as FcRn inhibitors, B-cell–depleting agents, and complement inhibitors offer more targeted mechanisms of action and are increasingly competing with IVIG in diseases like MG, ITP, and CIDP. These alternatives may reduce the long-term reliance on IVIG.
• Adverse Events & Safety Concerns: Although generally well tolerated, IVIG carries risks such as thromboembolic events, renal dysfunction, aseptic meningitis, and infusion-related reactions. Growing scrutiny of safety signals, particularly associated with activated coagulation factors like FXIa—has intensified regulatory vigilance.

Request a free sample copy or view report summary: Intravenous Immunoglobulin Market Report

 

Scope of the Intravenous Immunoglobulin Market Report:

 

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Intravenous Immunoglobulin Companies: Shanghai RAAS Blood Products Co. Ltd, Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd, Biotest AG, CSL Behring, Grifols SA, Kedrion SpA, LFB Biotechnologies SAS, BDI Pharma Inc., China Biologic Products Holdings Inc., Hualan Biological Engineering Inc, ADMA Biologics Inc, and others
• Intravenous Immunoglobulin Therapeutic Assessment: Intravenous Immunoglobulin current marketed and Intravenous Immunoglobulin emerging therapies
• Intravenous Immunoglobulin Market Dynamics: Intravenous Immunoglobulin market drivers and Intravenous Immunoglobulin market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Intravenous Immunoglobulin Unmet Needs, KOL’s views, Analyst’s views, Intravenous Immunoglobulin Market Access and Reimbursement

 

About DelveInsight

 

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.